Blood and tissue study for B-cell lymphoma treatments
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at how well newer antibody treatments work for B-cell non-Hodgkin lymphoma. It uses blood and tissue samples to learn more about the treatment, which may help guide better care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have been diagnosed with B-cell non-Hodgkin lymphoma.
- You have already joined the FIL_MAB trial (the main treatment study).
- Your doctor has planned for you to receive new monoclonal antibody treatments, either alone or with other medicines.
- You are willing to give blood and tissue samples for research.
- Your overall health is stable with no serious uncontrolled infections like HIV, hepatitis B, or hepatitis C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how “circulating tumor DNA” in blood changes in people with newly diagnosed primary mediastinal large B-cell lymphoma. It may help doctors better monitor treatment response alongside standard PET/CT-guided care, which could improve follow-up decisions.
This study watches how newer monoclonal antibodies (targeted therapies) work for people with B-cell non-Hodgkin lymphoma in real-world Italian clinics. It helps doctors learn more about how these treatments affect patients in everyday care.
This study collects blood and tumor tissue samples from people newly diagnosed with aggressive non-Hodgkin lymphoma who will receive standard chemotherapy. The goal is to improve future tests for detecting minimal residual disease (tiny amounts of cancer left after treatment).
This trial tests a medicine called MBS303 to see how safe it is and how well it works in adults with B-cell non-Hodgkin lymphoma (NHL) that has come back or did not respond to prior anti-CD20 treatment. It may help people who have few or no treatment options expected to improve survival.
This trial tests a new mRNA treatment that helps your immune cells target and attack lymphoma cells. It's for people whose B-cell non-Hodgkin lymphoma has come back or not responded to prior treatments.
This early-stage study tests a new medicine (BGB-16673) that targets B-cell cancer cells in people with specific lymphoma or related blood cancers. It aims to see how well the drug can control the cancer and what side effects it causes, especially in Chinese participants.
Hear when a new B-Cell Non-Hodgkin Lymphoma (NHL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.